FDMT vs. CRSP, KRYS, IBRX, IMVT, SWTX, APGE, IOVA, ACLX, DNLI, and TWST
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), Denali Therapeutics (DNLI), and Twist Bioscience (TWST). These companies are all part of the "biological products, except diagnostic" industry.
4D Molecular Therapeutics (NASDAQ:FDMT) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.
4D Molecular Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, CRISPR Therapeutics had 17 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 21 mentions for CRISPR Therapeutics and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.10 beat CRISPR Therapeutics' score of 0.71 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.
4D Molecular Therapeutics has a beta of 2.94, indicating that its share price is 194% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.
CRISPR Therapeutics received 426 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 65.43% of users gave CRISPR Therapeutics an outperform vote while only 65.38% of users gave 4D Molecular Therapeutics an outperform vote.
4D Molecular Therapeutics currently has a consensus price target of $44.22, suggesting a potential upside of 75.83%. CRISPR Therapeutics has a consensus price target of $73.57, suggesting a potential upside of 33.19%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than CRISPR Therapeutics.
99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
CRISPR Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -436.30%. CRISPR Therapeutics' return on equity of -11.56% beat 4D Molecular Therapeutics' return on equity.
Summary
4D Molecular Therapeutics beats CRISPR Therapeutics on 11 of the 18 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
